Cambridge NeuroScience Inc. has received a U.S. patent, No.5,262,568, for the composition of Cerestat as well as for otherchemical structures for more than 100 different compoundsthat are similar in structure to Cerestat.
In addition, the U.S. Patent and Trademark Office has allowedtwo additional patents, one covering methods of use to treatdiseases of the central nervous system for all these compoundsand another covering the manufacturing process for Cerestatand related compounds.
Cambridge NeuroScience (NASDAQ:CNSI) of Cambridge, Mass., iscurrently testing Cerestat in Phase Ib safety trials in the U.S.and the U.K. in patients who have suffered acute strokes.
Phase II efficacy studies for prevention of brain damage inpatients with stroke and traumatic brain injury are scheduledto begin in 1994. The drug acts by blocking the flow of calciuminto brain cells, which leads to cell death and brain damage. --Brenda Sandburg
(c) 1997 American Health Consultants. All rights reserved.